Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DB-1310 in Advanced/Metastatic Solid Tumors
NCT05785741Phase 2Recruiting
- Sponsor
- Duality Biotherapeutics
- Start
- Aug 2023
- Primary completion
- Dec 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of db-1310 in solid tumor, non-small cell lung cancer (NSCLC), castration-resistant prostate cancer (CRPC), head and neck squamous cell carcinoma (HNSCC), breast cancer, sponsored by Duality Biotherapeutics. Started Aug 2023; status: recruiting.
02
Drugs
db-1310
03
Conditions
solid tumornon-small cell lung cancer (NSCLC)castration-resistant prostate cancer (CRPC)head and neck squamous cell carcinoma (HNSCC)breast cancer
Beyond the preview
Go deeper on NCT05785741.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05785741.